Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Sanofi
Deal Size : $1,025.0 million
Deal Type : Collaboration
Details : The agreement grants Sanofi non-exclusive rights to Scribe’s proprietary CRISPR platform of wholly owned enzymes to create ex vivo NK cell therapies for multiple oncology targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $25.0 million
September 27, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Sanofi
Deal Size : $1,025.0 million
Deal Type : Collaboration